OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Status:
Completed
Trial end date:
2020-10-16
Target enrollment:
Participant gender:
Summary
This is a phase 3, randomized, multi-center, single dose, open label, pivotal study in
patients diagnosed with, or with high clinical suspicion of, ovarian cancer scheduled to
undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer
surgery.